Recent market activity shows Director Peter Farrell and CFO Brett Sandercock made significant sales of ResMed Inc (RMD) shares. Meanwhile, firms like Lake Street Advisors Group and Oxbow Advisors have boosted their holdings. Analysts exhibit a mixed outlook, with Needham downgrading ResMed, while others view it as a strong growth stock or see a potential undervaluation up to 28%. Insiders have sold $16 million of shares, indicating possible hesitancy. Earnings reports generally surpass estimates and margins are expanding, leading to increased dividends to shareholders. However, Eli Lilly's weight-loss drug has impacted ResMed negatively, causing stock to tumble. Despite this, attractive financial prospects are evident, with institutional investors controlling 74% of ResMed's shares, leading to a stock increase of 8.1%. Notably, ResMed's five-year earnings growth trails favorable shareholder returns. The company announced its participation in the Morgan Stanley Healthcare Conference and introduced the smallest full-face CPAP mask AirFit F40. They also reported plans to treat sleep apnea with the new AirCurve 11 device. Nonetheless, the FDA identified the recall of ResMed's respiratory devices as serious. On the bright side, ResMed's Q3 earnings surpassed analyst expectations.
Resmed RMD News Analytics from Fri, 12 Jan 2024 08:00:00 GMT to Sun, 08 Sep 2024 14:25:48 GMT - Rating 4 - Innovation 2 - Information 6 - Rumor 3
